Weekly Pharma & Life Science News Round Up: 4th – 8th July

A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 4^th-8^th July.

BeiGene announces strategic research collaboration with InnoRNA to jointly discover novel mRNA therapies

BeiGene announces it has entered into a worldwide strategic collaboration with InnoRNA to leverage its innovative technology platform for developing mRNA-based therapeutics.

Turnstone Biologics and Moffitt Cancer Center announce strategic alliance to advance next-generation TIL therapies for solid tumors

Turnstone Biologics Corp. and Moffitt Cancer Center announce the formation of a broad strategic alliance, deepening their existing multi-year research collaboration.

Labcorp first national laboratory to offer monkeypox test

Labcorp announces it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox.

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, the life science company Evotec SE and bioMérieux announce that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

Evotec completes acquisition of Rigenerand

Evotec announce that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward.

Novartis Pharmaceuticals UK launches world-first health-tech investor partnership to reimagine cardiovascular care

Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.

Platelet Services doubles lab footprint at BioCity Nottingham

Nottingham-based pre-clinical contract research organisation (CRO) Platelet Services has signed a new lease to double its lab scape at BioCity Nottingham, reflecting the year-on-year doubling of demand for the company’s core platelet function testing offering.

ProteoGenix doubles R&D facilities to pave the way for minimal animal use in biologics development

ProteoGenix is pleased to announce the expansion of its offices and R&D facilities in the north of Strasbourg, France.

Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries

Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.

Innovative Trials acquires first US office as part of mission to support patient access to clinical trials

Innovative Trials, a global clinical trial patient recruitment, retention and engagement company, has opened its first international office in the US, signalling its commitment to accelerating patient access to life-changing treatments within North America.

ADVANZ PHARMA completes acquisition of Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

ADVANZ PHARMA announces that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S.

Eckert & Ziegler becomes contract manufacturer for clinical development candidates based on Lutetium- 177 and Actinium- 225

Eckert & Ziegler has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu- 177 and Ac- 225.

Destiny Pharma announces start of a new XF-73 research programme

Destiny Pharma plc, a clinical-stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it has started a new research programme.

CD BioSciences to offer cell death solutions to advance life science research

To assist life science laboratories advancing productivity of cell death research and freeing up time for more value-added activities, CD BioSciences is offering a comprehensive panel of research solutions covering all aspects of cell death study.

Catalent announces new operating structure

Catalent, Inc., the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announces changes to its operating structure and executive leadership team.